Stoke Therapeutics, Inc. (NASDAQ:STOK) Given Average Recommendation of “Buy” by Brokerages

Shares of Stoke Therapeutics, Inc. (NASDAQ:STOK) have been assigned an average rating of “Buy” from the eight analysts that are presently covering the stock, Marketbeat Ratings reports. Seven investment analysts have rated the stock with a buy recommendation and one has given a strong buy recommendation to the company. The average 12 month price target among brokerages that have issued ratings on the stock in the last year is $24.67.

A number of research firms have commented on STOK. Cantor Fitzgerald restated an “overweight” rating on shares of Stoke Therapeutics in a research report on Tuesday, December 10th. Chardan Capital reaffirmed a “buy” rating and set a $24.00 price objective on shares of Stoke Therapeutics in a research note on Wednesday, March 19th. Needham & Company LLC restated a “buy” rating and set a $22.00 price target on shares of Stoke Therapeutics in a report on Tuesday, March 18th. Finally, HC Wainwright reiterated a “buy” rating and issued a $47.00 price objective on shares of Stoke Therapeutics in a research note on Wednesday, March 19th.

Insiders Place Their Bets

In other Stoke Therapeutics news, insider Barry Ticho sold 3,884 shares of the stock in a transaction that occurred on Tuesday, March 18th. The stock was sold at an average price of $8.67, for a total transaction of $33,674.28. Following the transaction, the insider now owns 63,962 shares in the company, valued at $554,550.54. This trade represents a 5.72 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Edward M. Md Kaye sold 10,382 shares of Stoke Therapeutics stock in a transaction that occurred on Tuesday, March 18th. The shares were sold at an average price of $8.67, for a total transaction of $90,011.94. Following the completion of the transaction, the director now directly owns 148,253 shares in the company, valued at approximately $1,285,353.51. This represents a 6.54 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 16,532 shares of company stock valued at $143,332 over the last three months. 11.30% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Stoke Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in STOK. Toronto Dominion Bank acquired a new position in shares of Stoke Therapeutics during the 4th quarter worth about $35,001,000. RTW Investments LP increased its position in Stoke Therapeutics by 10.1% in the 4th quarter. RTW Investments LP now owns 5,123,525 shares of the company’s stock worth $56,512,000 after buying an additional 471,240 shares during the period. Norges Bank acquired a new position in shares of Stoke Therapeutics during the fourth quarter worth approximately $3,472,000. Tang Capital Management LLC bought a new stake in shares of Stoke Therapeutics in the fourth quarter valued at approximately $3,309,000. Finally, Schonfeld Strategic Advisors LLC acquired a new stake in shares of Stoke Therapeutics in the fourth quarter worth $3,218,000.

Stoke Therapeutics Stock Down 4.4 %

STOK stock opened at $7.40 on Friday. The stock has a market cap of $400.18 million, a PE ratio of -3.52 and a beta of 0.99. The firm’s 50-day simple moving average is $9.40 and its 200 day simple moving average is $11.27. Stoke Therapeutics has a fifty-two week low of $7.18 and a fifty-two week high of $17.58.

Stoke Therapeutics (NASDAQ:STOK) last announced its quarterly earnings results on Monday, March 24th. The company reported ($0.18) EPS for the quarter, beating the consensus estimate of ($0.56) by $0.38. Stoke Therapeutics had a negative net margin of 629.90% and a negative return on equity of 54.45%. The company had revenue of $22.61 million for the quarter, compared to analyst estimates of $4.20 million. Equities analysts forecast that Stoke Therapeutics will post -2.01 EPS for the current fiscal year.

Stoke Therapeutics Company Profile

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.